Aptus Pharma Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vjxrn88h2ltp4qp48vpdfk0e.pdf

Key Takeaways


Revenue Growth & Profitability

Tejash Hathi: "Revenue growth is an important indicator for the business momentum, but the objective is to convert the momentum into a sustainable, profitable and financially sound operating structure."

Portfolio Mix & Therapy Strategy

Tejash Hathi: "We believe that the quality of growth matters as much as the pace of growth. Our intention is to develop a business that can maintain a sound financial foundation while increasing its scale over time."

Geographic Expansion

Tejash Hathi: "Our clear vision and target by 2029 is Pan India presence of our company with our own manufacturing facility as well as expanding our product portfolio."

Manufacturing Integration

Tejash Hathi: "Absolutely not. We will not go for the CDMO. The plant will be dedicated for self-consumption."

International & Long-Term Roadmap

Tejash Hathi: "We believe that sustainable value creation comes from building a strong business step-by-step rather than pursuing expansion without considering the financial and operational implications."

Guidance Policy & Unanswered Questions

Tejash Hathi: "Sir, let me say first; at present we are not going to give any forward figure. So, at present, we are not giving the guideline regarding the EBITDA or topline or bottom line at present right now."

Guidance & Commitments

CommitmentSpecificsTimeline
Geographic coverageAchieve 46% geographic coverage across IndiaBy March 2027
Pan-India presenceProducts available in every medical store across more than 8.5 lakh pharmaciesBy 2029
Manufacturing self-sufficiencyDevelop approximately 20% of the product portfolio through own manufacturing capabilitiesBy March 2028
Manufacturing funding₹25 crore of the ₹35 crore CAPEX funded from the ongoing preferential issueSubject to exchange approval
Portfolio balanceStrengthen acute and chronic therapy portfolio while developing opportunities across all categoriesOngoing

Key Metrics

MetricH1 FY27
Revenue from operations₹48.90 cr (H1 FY27), vs ₹14.38 cr in H1 FY26
Total income₹48.96 cr (H1 FY27)
EBITDA₹7.68 cr (H1 FY27)
Profit before tax₹6.83 cr (H1 FY27)
Profit after tax₹5.08 cr (H1 FY27)
Acute therapy revenue share44% of sales
Chronic and semi-chronic therapies revenue sharearound 20% of sales
Wellness and OTC products revenue shareapproximately 20% of sales
Sales of services revenue sharearound 16% of revenue
Total assets₹54.55 cr as of 30th September 2026
Inventory₹16.25 cr as of 30th September 2026
Trade receivables₹28.64 cr as of 30th September 2026
Product portfolio300+ formulations
Distribution network250+ distributors and sub-distributors
Retail availability45,000+ outlets
Doctor coverage10,000+ doctors
Front-line Medical Representatives on roll142
Total on-roll and off-roll professionals150+
Sales representatives in distribution networks200+
Attrition ratioBelow 5%–6%
Planned manufacturing CAPEX (initial phase)₹35 cr
CAPEX to be funded from preferential issue₹25 cr
Target geographic coverage by March 202746% of India
Target in-house manufacturing by March 202820% of product portfolio
Target pan-India footprint2029